Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan‐cancer setting

MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis

(2018) Sadakatsu Ikeda et al.   Journal of Hematology & Oncology

KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer

(2018) Francesco Sclafani et al.   Scientific Reports

Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

(2018) Shumei Kato et al.   CLINICAL CANCER RESEARCH

Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer

(2018) Vincent Bernard et al.   GASTROENTEROLOGY

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer

(2017) Alexander W Wyatt et al.   JNCI-Journal of the National Cancer Institute

Blood-based detection ofRASmutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-basedRAStesting

(2017) Wolff Schmiegel et al.   Molecular Oncology

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer

(2017) Alexander W Wyatt et al.   JNCI-Journal of the National Cancer Institute

The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis

(2017) Rongyuan Zhuang et al.   PLoS One

Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study

(2016) Jennifer J. Wheler et al.   CANCER RESEARCH

Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients

(2016) Maria Schwaederle et al.   CLINICAL CANCER RESEARCH

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA

(2016) Marzia Del Re et al.   Oncotarget

Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer

(2016) Evelyn Kidess-Sigal et al.   Oncotarget

Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay

(2016) Maria Schwaederle et al.   Oncotarget

Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms

(2016) Maria Schwaederle et al.   JAMA Oncology

Cell-free DNA as a novel marker in cancer therapy

(2015) Shumei Kato et al.   Biomarkers in Medicine

Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes

(2015) Razelle Kurzrock et al.   CELL CYCLE

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

(2015) T. Mok et al.   CLINICAL CANCER RESEARCH

On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients

(2015) M. Schwaederle et al.   MOLECULAR CANCER THERAPEUTICS

Comparison of Genetic and Epigenetic Alterations of Primary Tumors and Matched Plasma Samples in Patients with Colorectal Cancer

(2015) Elisa Danese et al.   PLoS One

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA

(2015) Richard B. Lanman et al.   PLoS One

Oncogenic KRAS signalling in pancreatic cancer

(2014) S Eser et al.   BRITISH JOURNAL OF CANCER

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

(2013) Garrett M Frampton et al.   NATURE BIOTECHNOLOGY

Intratumor Heterogeneity: Evolution through Space and Time

(2012) C. Swanton   CANCER RESEARCH

A Comprehensive Survey of Ras Mutations in Cancer

(2012) I. A. Prior et al.   CANCER RESEARCH

Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer

(2012) Amanda K. Arrington et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors

(2012) Ignacio Garrido-Laguna et al.   PLoS One